Has Andrew Klompus received payments from drug or device companies?

Yes. Drug and device makers reported $10,175 in general payments to Andrew Klompus across 353 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Andrew Klompus did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Andrew Klompus come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Andrew Klompus

Psychiatry · San Francisco, CANPI 1215001771

Payments from drug & device makers

$10,175in general payments, 2019–2025

Across 353 payments — averaging $28.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$2K
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
Axsome Therapeutics, Inc.$990
Alkermes, Inc.$907
Otsuka America Pharmaceutical, Inc.$903
Neurocrine Biosciences, Inc.$896
plus $4K from 16 others

What the payments were for

Food & beverage$10,129100%
Education$460%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	68	$1,612
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	35	$1,219
Axsome Therapeutics, Inc.	17	$990
Alkermes, Inc.	29	$907
Otsuka America Pharmaceutical, Inc.	28	$903
Neurocrine Biosciences, Inc.	18	$896
Takeda Pharmaceuticals U.S.A., Inc.	44	$855
Bausch Health US, LLC	32	$574
Johnson & Johnson	10	$446
Lundbeck LLC	35	$432
Teva Pharmaceuticals USA, Inc.	5	$385
Sunovion Pharmaceuticals Inc.	3	$200
Tris Pharma Inc	3	$147
Shire North American Group Inc	8	$146
Vanda Pharmaceuticals Inc.	5	$130
Supernus Pharmaceuticals, Inc.	2	$102
Avanir Pharmaceuticals, Inc.	5	$92
Adlon Therapeutics L.p.	2	$49
E.r. Squibb & Sons, L.L.C.	1	$27
Bioxcel Therapeutics, Inc.	1	$26
Jazz Pharmaceuticals Inc.	1	$25
Merck	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,175 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
TrintellixVortioxetine Hydrobromide	50	$30,690
LybalviOlanzapine/Samidorphan Malate	12	$18,697
CaplytaLumateperone Tosylate	11	$17,462
VyvanseLisdexamfetamine Dimesylate	12	$5,310
Modafinil	11	$3,479
Bupropion XlBupropion Hcl	12	$2,967
Clonazepam	40	$1,042
Escitalopram Oxalate	65	$676
Olanzapine	45	$591
Divalproex Sodium	29	$564
Quetiapine Fumarate	37	$537
Venlafaxine Hcl ErVenlafaxine Hcl	20	$515
Methylphenidate Hcl	14	$484
Propranolol Hcl	25	$409
Bupropion Hcl SrBupropion Hcl	12	$396

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse	$855	$35,99962 claims
Alkermes, Inc.Lybalvi	$907	$18,69712 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta	$1,219	$17,46211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.

Other psychiatry in San Francisco

John KooSan Francisco$3M
Corinna GamezSan Francisco$2M
Elly LeeIrvine$49.8M
Daniel ChuehOrange$17.9M
Eric ChavezSan Diego$15.5M
Lara ShirikjianTorrance$12.6M
John DuffySanta Ana$12M
Marina BusselPlaya Vista$12M
Sherry SoefjeOceanside$11.9M
Steven MacinaHuntington Beach$11.1M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →